达格列净对伴或不伴2型糖尿病的慢性肾病患者尿白蛋白排泄的影响:DAPA-CKD试验预设分析
DAPA-CKD预设分析纳入4304例慢性肾病患者,随机接受达格列净10mg每日一次或安慰剂。达格列净增加UACR分期逆转可能性并降低进展风险。
要点
- 达格列净显著降低慢性肾病患者尿白蛋白排泄,2型糖尿病患者降幅更大。
- 达格列净增加UACR分期逆转并降低进展风险。
- 早期UACR下降幅度越大,后续eGFR下降越慢。
核心结论
- 在伴或不伴2型糖尿病的慢性肾病患者中,达格列净显著降低白蛋白尿,2型糖尿病患者相对降幅更大。
- 达格列净对伴或不伴2型糖尿病患者的临床结局影响相似但UACR影响不同,提示部分保护作用可能不依赖白蛋白尿减少。
研究设计与样本
- DAPA-CKD为多中心、双盲、安慰剂对照随机试验,在21个国家386个中心进行。
- 共4304例患者随机分配至达格列净10mg每日一次(n=2152)或安慰剂(n=2152)。
- 白蛋白尿变化为预设探索性结局。
主要发现
- 中位UACR为949 mg/g(IQR 477-1885)。
临床怎么用
- 慢性肾病患者可考虑使用达格列净10mg每日一次以降低白蛋白尿。
- 伴2型糖尿病的慢性肾病患者使用达格列净可能获得更大的白蛋白尿降幅。
- 早期UACR下降幅度可作为后续肾功能保护的参考指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Reductions in albuminuria are associated with a subsequent lower risk of kidney failure in patients with chronic kidney disease. The SGLT2 inhibitor dapagliflozin significantly reduced albuminuria in patients with type 2 diabetes and normal or near-normal kidney function. Whether this effect persists in patients with chronic kidney disease with and without type 2 diabetes is unknown. We assessed the effects of dapagliflozin on albuminuria in patients with chronic kidney disease with and without type 2 diabetes in the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. METHODS: DAPA-CKD was a multicentre, double-blind, placebo-controlled, randomised trial done at 386 sites in 21 countries. Patients were eligible for the trial if they had chronic kidney disease, defined as an estimated glomerular filtration rate (eGFR) between 25 mL/min per 1·73 m2 and 75 mL/min per 1·73 m2 and a urinary albumin-to-creatinine ratio (UACR) between 200 mg/g and 5000 mg/g (22·6 to 565·6 mg/mmol). Participants were randomly assigned to dapagliflozin 10 mg (AstraZeneca; Gothenburg, Sweden) once daily or matching placebo, in accordance with the sequestered, fixed randomisation schedule, using balanced blocks to ensure an approximate 1:1 ratio. Change in albuminuria was a pre-specified exploratory outcome of DAPA-CKD. Regression in UACR stage, defined as a transition from macroalbuminuria (≥300 mg/g) to microalbuminuria or normoalbuminuria (<300 mg/g), and progression in UACR stage, defined as a transition from less than 3000 mg/g to 3000 mg/g or greater, were additional discrete endpoints. The trial is registered with ClinicalTrials.gov, NCT03036150. FINDINGS: Between Feb 2, 2017, and April 3, 2020, 4304 patients were recruited and randomly assigned to either dapagliflozin (n=2152) or placebo (n=2152). Median UACR was 949 mg/g (IQR 477 to 1885). Overall, compared with placebo, dapagliflozin reduced geometric mean UACR by 29·3% (95% CI -33·1 to -25·2; p<0·0001); relative to placebo, treatment with dapagliflozin resulted in a geometric mean percentage change of -35·1% (95% CI -39·4 to -30·6; p<0·0001) in patients with type 2 diabetes and -14·8% (-22·9 to -5·9; p=0·0016) in patients without type 2 diabetes over the follow-up visits (pinteraction<0·0001) Among 3860 patients with UACR of 300 mg/g or greater at baseline, dapagliflozin increased the likelihood of regression in UACR stage (hazard ratio 1·81, 95% CI 1·60 to 2·05). Among 3820 patients with UACR less than 3000 mg/g at baseline, dapagliflozin decreased the risk of progression in UACR stage (0·41, 0·32 to 0·52). Larger reductions in UACR at day 14 during dapagliflozin treatment were significantly associated with attenuated eGFR decline during subsequent follow-up (β per log unit UACR change -3·06, 95% CI -5·20 to -0·90; p=0·0056). INTERPRETATION: In patients with chronic kidney disease with and without type 2 diabetes, dapagliflozin significantly reduced albuminuria, with a larger relative reduction in patients with type 2 diabetes. The similar effects of dapagliflozin on clinical outcomes in patients with or without type 2 diabetes, but different effects on UACR, suggest that part of the protective effect of dapagliflozin in patients with chronic kidney disease might be mediated through pathways unrelated to reduction in albuminuria. FUNDING: AstraZeneca.
引用
- Jongs N, Greene T, Chertow GM, et al. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021. PMID: 34619106. doi:10.1016/S2213-8587(21)00243-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。